Nifib (Nintedanib Esylate)

Nintedanib inhibits multiple receptor tyrosine kinases—VEGFR, FGFR and PDGFR—thereby blocking signals that promote fibroblast growth, extracellular matrix formation, and new blood‑vessel development. This multi‑targeted inhibition reduces fibrotic tissue buildup in the lungs and limits the blood supply that tumors need to grow.

The specific dose of Nifib is determined by the prescribing physician based on the patient’s condition, weight, renal and hepatic function, and other clinical factors. Healthcare providers follow approved labeling and adjust the regimen as needed for safety and efficacy.

Safety data for nintedanib in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception, and breastfeeding mothers should discuss risks with their healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nifib (nintedanib) differs from other antifibrotics such as pirfenidone by targeting a broader range of tyrosine kinases, which may provide additional anti‑angiogenic benefits in cancer settings. Clinical trials have shown comparable efficacy in slowing lung function decline in idiopathic pulmonary fibrosis, while offering a distinct safety profile that clinicians consider when selecting therapy.

Nifib should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Nifib is taken orally, usually as a tablet, with food to reduce gastrointestinal discomfort. The exact administration schedule—such as once or twice daily—depends on the prescriber’s instructions and the specific indication being treated.

The most serious risks include liver enzyme elevations that may indicate hepatotoxicity, significant bleeding events especially when combined with anticoagulants, cardiovascular complications like hypertension, and rare but severe gastrointestinal perforations. Patients should be monitored regularly for these adverse outcomes.

Nifib is contraindicated in patients with severe hepatic impairment, active bleeding disorders, uncontrolled hypertension, or known hypersensitivity to nintedanib or any excipients. It should also be used with caution in individuals with a history of gastrointestinal ulcers or perforation.